As of Dec 15
| 0.00 / 0.00%|
The 7 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 13.00, with a high estimate of 16.00 and a low estimate of 10.00. The median estimate represents a -4.41% decrease from the last price of 13.60.
The current consensus among 7 polled investment analysts is to Hold stock in Momenta Pharmaceuticals Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.